Logo image of NAYA

NAYA BIOSCIENCES INC (NAYA) Stock Price, Quote, News and Overview

NASDAQ:NAYA - Nasdaq - US44984F4019 - Common Stock - Currency: USD

0.461  +0 (+0.22%)

After market: 0.4999 +0.04 (+8.44%)

NAYA Quote, Performance and Key Statistics

NAYA BIOSCIENCES INC

NASDAQ:NAYA (2/4/2025, 8:00:01 PM)

After market: 0.4999 +0.04 (+8.44%)

0.461

+0 (+0.22%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap2.28M
Shares4.94M
Float4.86M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO11-11 2008-11-11


NAYA short term performance overview.The bars show the price performance of NAYA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

NAYA long term performance overview.The bars show the price performance of NAYA in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of NAYA is 0.461 USD. In the past month the price decreased by -47.02%.

NAYA BIOSCIENCES INC / NAYA Daily stock chart

NAYA Latest News, Press Releases and Analysis

News Image
23 days ago - NAYA Biosciences, Inc.

NAYA Biosciences Announces Pricing of $9.5 Million Public Offering

SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to...

News Image
a month ago - NAYA Biosciences, Inc.

NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

•  PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications •  NAYA aiming to initiate...

News Image
3 months ago - NAYA Biosciences, Inc.

NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Abstracts demonstrate reversal of resistance to PD1 checkpoint blockade and predictive AI model of HCC survival rate...

News Image
3 months ago - NAYA Biosciences, Inc.

NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma

SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to...

NAYA Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 27.64 223.92B
ISRG INTUITIVE SURGICAL INC 79.08 206.46B
BSX BOSTON SCIENTIFIC CORP 43.87 152.60B
SYK STRYKER CORP 32.19 149.59B
MDT MEDTRONIC PLC 17.33 116.65B
BDX BECTON DICKINSON AND CO 18.42 70.30B
EW EDWARDS LIFESCIENCES CORP 26.72 42.07B
GEHC GE HEALTHCARE TECHNOLOGY 20.6 39.72B
IDXX IDEXX LABORATORIES INC 41.34 38.08B
RMD RESMED INC 27.2 35.30B
DXCM DEXCOM INC 51.45 34.16B
PHG KONINKLIJKE PHILIPS NVR- NY 20.23 25.29B

About NAYA

Company Profile

NAYA logo image INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.

Company Info

NAYA BIOSCIENCES INC

5582 Broadcast Court

Sarasota FLORIDA US

Employees: 25

Company Website: https://www.invobioscience.com/

Investor Relations: http://www.invobioscience.com/investors/

Phone: 19788789505

NAYA FAQ

What is the stock price of NAYA?

The current stock price of NAYA is 0.461 USD.


What is the symbol for NAYA BIOSCIENCES INC stock?

The exchange symbol of NAYA BIOSCIENCES INC is NAYA and it is listed on the Nasdaq exchange.


On which exchange is NAYA stock listed?

NAYA stock is listed on the Nasdaq exchange.


Is NAYA a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for NAYA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of NAYA.


Does NAYA stock pay dividends?

NAYA does not pay a dividend.


What is the Price/Earnings (PE) ratio of NAYA?

NAYA does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.96).


What is the Short Interest ratio of NAYA stock?

The outstanding short interest for NAYA is 7.08% of its float.


NAYA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to NAYA.


Chartmill TA Rating
Chartmill Setup Rating

NAYA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NAYA. NAYA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NAYA Financial Highlights

Over the last trailing twelve months NAYA reported a non-GAAP Earnings per Share(EPS) of -2.96. The EPS decreased by 76.18% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -43.87%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%40.05%
Sales Q2Q%47.75%
EPS 1Y (TTM)76.18%
Revenue 1Y (TTM)224.36%

NAYA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to NAYA. The Buy consensus is the average rating of analysts ratings from 6 analysts.

For the next year, analysts expect an EPS growth of -222.5% and a revenue growth 199.65% for NAYA


Ownership
Inst Owners3.1%
Ins Owners0.63%
Short Float %7.08%
Short Ratio2.07
Analysts
Analysts43.33
Price Target2.04 (342.52%)
EPS Next Y-222.5%
Revenue Next Year199.65%